Trial Profile
A phase II study of preoperative capecitabine and concomitant radiation in women with advanced inflammatory or non-inflammatory breast cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2018
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
- 16 May 2013 Planned end date changed from 1 Jul 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov.
- 19 Jan 2012 Inclusion criteria amended as reported by ClinicalTrials.gov.